Key Market Indicator:
Ad-hoc news is mandatory information from listed companies that must be made available to investors. Depending on the occasion and content of the news, it can have an impact on the share price. The newsfeed covers a wide range of topics relevant to investor relations and is recommended as an important source of information before making an investment decision.
DE000A2GS5D8
Wed, 22.03.2023
Dermapharm Holding SE
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse(Market Abuse Regulation, "MAR")
Dermapharm Holding SE: 2022 dividend
Grünwald, 22 March 2023 – At its meeting today, the Board of Management of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) resol [ … ]
Wed, 22.03.2023
Dermapharm Holding SE
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse(Market Abuse Regulation, "MAR")
Dermapharm Holding SE: 2022 dividend
Grünwald, 22 March 2023 – At its meeting today, the Board of Management of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) resol [ … ]
Sat, 30.07.2022
Dermapharm Holding SE
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation – MAR)
Dermapharm Holding SE: binding offer to acquire Arkopharma Group
Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D [ … ]
Sat, 30.07.2022
Dermapharm Holding SE
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation – MAR)
Dermapharm Holding SE: binding offer to acquire Arkopharma Group
Grünwald, July 30, 2022 – Today, Dermapharm AG, wholly owned subsidiary of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D [ … ]
Thu, 16.12.2021
Dermapharm Holding SE
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation - MAR)
Dermapharm Holding SE raises EBITDA forecast for the full year 2021
Grünwald, December 16, 2021 - The Management Board of Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) analysed the bu [ … ]
Wed, 15.12.2021
Dermapharm Holding SE
Disclosure of insider information pursuant to Section 17 (1) 1 of Regulation (EU)
No. 596/2014 on market abuse, as amended
(Market Abuse Regulation - MAR)
Dermapharm Holding SE: Acquisition of C³ Cannabinoid Compound Company GmbH
Grünwald, December 15, 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8), through Dermapharm AG, today en [ … ]
Wed, 07.07.2021
Dermapharm Holding SE
Public disclosure of inside information in accordance with the amended version of Article 17(1) of Regulation (EU) No 596/2014 on market abuse (Market Abuse Regulation, "MAR")
Dermapharm Holding SE acquires equity investment in CORAT Therapeutics GmbH
Grünwald, 7 July 2021 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) today, via Derma [ … ]
Thu, 10.09.2020
Dermapharm Holding SE
Disclosure of Insider Information pursuant to Section 17 (1) 1 of the Regulation (EU)
No. 596/2014 on Market Abuse, as amended
(Market Abuse Regulation - MAR)
Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE
Grünwald, September 10, 2020 - Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Ma [ … ]